A clinical study for people recently diagnosed with glioblastoma

A research study is evaluating a new investigational approach that combines an oral medication with non-invasive, low-intensity ultrasound.

See if you are eligible button-arrow

About the study

What this study is evaluating

This study is testing a new investigational therapy for adults who have recently been diagnosed with glioblastoma (GBM). The approach combines an oral medication with low-intensity ultrasound delivered through a specialized treatment system. The goal is to learn whether activating a compound that naturally builds up in tumor cells may help doctors target cancer cells in a new way.

The investigational therapy is added on top of the standard treatment most patients already receive (surgery, radiation, and temozolomide). All patients continue standard care.

This therapy is not approved, and its safety and effectiveness are still being studied.

How it works

A two-step process under investigation

  • Oral medication

    Patients take a medication that causes certain compounds to build up more in tumor cells than in healthy brain cells.

  • Targeted ultrasound activation

    After the medication is absorbed, low-intensity ultrasound is delivered from outside the head. Researchers are studying whether this activation process may affect tumor cells while sparing surrounding healthy tissue.

Participation & Eligibility

What Participation Involves

If you’re eligible, participation may include:

  • Continuing standard treatment (radiation and temozolomide)
  • Monthly outpatient visits for the investigational therapy
  • MRI scans and routine follow-up
  • Ongoing check-ins with the study team

Participation is voluntary, and you may leave the study at any time.

Who May Be Eligible

You may be eligible if:

  • You are 18 to 80 years old
  • You have been recently diagnosed with glioblastoma
  • You have had, or are planning to have, surgery
  • You are scheduled for or completing standard radiation and temozolomide
  • Your tumor began in the brain (not from another cancer)

Final eligibility is determined by the study doctors.

Start the Qualification Check

Please answer a few quick questions. It should take less than one minute.
If the answers suggest you may qualify, a member of the team will call you to discuss next steps.

Questions?

If you have questions about the study, a team member can speak with you after the initial screening.

All study information shared here is general and for educational purposes only. Final eligibility and participation decisions are made by the study doctors.

Privacy Policy

Information submitted through this site is collected solely for the purpose of evaluating potential eligibility for participation in a clinical trial sponsored by Alpheus Medical, Inc. Any information you choose to provide may be shared with Alpheus Medical and its service providers, including Credent Partners USA, LLC, and, if appropriate, with clinical study sites, strictly for trial screening and participation-related purposes. This information will not be used for unrelated marketing or other purposes. For more information on how Alpheus Medical collects, uses, and protects personal information, please review our full Privacy Policy.

This study is evaluating an investigational therapy that is not approved by the FDA. Participation is voluntary. This website does not provide medical advice.

© 2026 Alpheus Medical Inc., All Rights Reserved. This site is intended for U.S. audiences only.